dc.contributor.author
Barton, Ann Kristin
dc.contributor.author
Pelli, Anna
dc.contributor.author
Rieger, Martin
dc.contributor.author
Gehlen, Heidrun
dc.date.accessioned
2018-06-08T11:07:26Z
dc.date.available
2017-02-02T12:03:21.285Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/21659
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-24947
dc.description.abstract
Background Procalcitonin (PCT), a precursor protein of the hormone calcitonin,
is a sensitive inflammatory marker in human medicine, which is primarily used
for diagnosis of bacterial sepsis, but is also useful in diagnosis of
exacerbation of asthma and COPD. In this study, PCT was evaluated as a
potential biomarker for different chronic pneumopathies in the horse using an
equine specific ELISA in comparison to established clinical markers and
different interleukins. Sixty-four horses were classified as free of
respiratory disease, recurrent airway obstruction (RAO), inflammatory airway
disease (IAD) or chronic interstitial pneumopathy (CIP) using a scoring
system. PCT concentrations were measured in plasma (n = 17) and in the cell-
free supernatant of bronchoalveolar lavage (n = 64). PCT concentrations were
correlated to interleukins IL-1ß and IL-6 in BALF, clinical findings and BALF
cytology. Results The median PCT concentrations in plasma were increased in
respiratory disease (174.46 ng/ml, n = 7) compared to controls (13.94 ng/ml, n
= 10, P = 0.05) and correlated to PCT in BALF supernatant (rs = 0.48).
Compared to controls (5.49 ng/ml, n = 15), median PCT concentrations in BALF
supernatant correlated to the overall clinical score (rs = 0.32, P = 0.007)
and were significantly increased in RAO (13.40 ng/ml, n = 21) and IAD (16.89
ng/ml, n = 16), while no differences were found for CIP (12.02 ng/ml, n = 12).
No significant increases were found for IL-1 and IL-6 between controls and
respiratory disease in general as well as different disease groups.
Conclusions Although some correlations were found between PCT in plasma, BALF
supernatant and clinical scores, PCT in BALF does not seem to be a superior
marker compared to established clinical markers. PCT in plasma seems to be
more promising and a greater number of samples should be evaluated in further
studies.
en
dc.rights.uri
http://creativecommons.org/licenses/by/4.0/
dc.subject
Recurrent airway obstruction
dc.subject
Inflammatory airway disease
dc.subject
Chronic interstitial pneumopathy
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::630 Landwirtschaft
dc.title
Procalcitonin as a biomarker in equine chronic pneumopathies
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation
BMC Veterinary Research. - 12 (2016), Artikel Nr. 281
dcterms.bibliographicCitation.doi
10.1186/s12917-016-0912-4
dcterms.bibliographicCitation.url
http://bmcvetres.biomedcentral.com/articles/10.1186/s12917-016-0912-4
refubium.affiliation
Veterinärmedizin
de
refubium.mycore.fudocsId
FUDOCS_document_000000026246
refubium.note.author
Der Artikel wurde in einer reinen Open-Access-Zeitschrift publiziert.
refubium.resourceType.isindependentpub
no
refubium.mycore.derivateId
FUDOCS_derivate_000000007614
dcterms.accessRights.openaire
open access